Kamada guided for robust 2026 organic growth: $200-$205M revenue and $50-$53M adjusted EBITDA, reflecting strong portfolio scalability. KMDA reaffirmed 2025 guidance ($178-$182M revenue, $40-$44M ...

Q4 2025 earnings call highlights: 2026 revenue $51B, 31.5% margin target, ads to $3B, and Warner Bros/HBO deal—read now.

When you buy through affiliate links in our content, we may earn a commission at no extra cost to you. Learn how our funding model works. By using this website you agree to our terms and conditions ...

CEO Seamus Grady highlighted "an exceptional start to fiscal 2026 with record revenue and earnings that exceeded our guidance ranges and demonstrated our continued business momentum." He noted Q1 ...

Akebia Therapeutics (NASDAQ:AKBA) posted $62.5 million in GAAP revenue for Q2 2025. GAAP revenue was $47.2 million, missing analyst estimates of $47.24 million. Net income (GAAP) reached $0.2 million, ...